Products for Research Use Only
RegisterLogin

Ribociclib

CAT: 0804-HY-15777-07Size: 500 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-15777-07Size:500 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
RRibociclib (LEE011) is an ATP-competitive and orally active CDK4/6 inhibitor with IC50 values of 10 nM and 39 nM, respectively, and is over 1,000-fold less potent against the cyclin B/CDK1 complex[1][1].
CAS Number
1211441-98-3
Product Name Alternative
LEE011
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
CDK
Type
Reference compound
Related Pathways
Cell Cycle/DNA Damage
Applications
Cancer-Kinase/protease
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/LEE011.html
Purity
99.94
Solubility
DMSO : 6.25 mg/mL (ultrasonic)
Smiles
O=C(N(C)C)C(N1C2CCCC2)=CC(C1=N3)=CN=C3NC(N=C4)=CC=C4N5CCNCC5
Molecular Formula
C23H30N8O
Molecular Weight
434.54
Precautions
H302, H315, H319, H335
References & Citations
[1]VanArsdale T, et al. Molecular Pathways: Targeting the Cyclin D-CDK4/6 Axis for Cancer Treatment. Clin Cancer Res. 2015 Jul 1;21 (13) :2905-10.|[2]Rader J, et al. Dual CDK4/CDK6 Inhibition Induces Cell-Cycle Arrest and Senescence in Neuroblastoma. Clin Cancer Res. 2013 Nov 15;19 (22) :6173-82.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
CDK4; CDK6
Citation 01
Artif Cells Nanomed Biotechnol. 2019 Dec;47 (1) :4001-4011.|Bioengineering (Basel) . 2025 Oct 19;12 (10) :1121.|Biomed Chromatogr. 2020 Mar;34 (3) :e4783.|Biomed Pharmacother. 2019 Apr:112:108602.|Biomed Res Int. 2020 Jun 11;2020:9525207.|bioRxiv. 2024 Nov 15:2024.11.11.623139.|bioRxiv. 2025 February 23.|bioRxiv. 2025 Nov 3:2025.11.02.685764.|bioRxiv. 2025 Sep 15.|Breast Cancer Res. 2019 Dec 26;21 (1) :150.|Cancer Cell. 2024 Aug 27:S1535-6108 (24) 00305-2.|Cancer Discov. 2024 Mar 1;14 (3) :446-467.|Cancer Res. 2019 Oct 15;79 (20) :5245-5259.|Cancer Res. 2025 Apr 3;85 (7) :1297-1309.|Cancers (Basel) . 2022 Nov 8;14 (22) :5481.|Cancers. 2020 Jun 16;12 (6) :1596.|Cell Chem Biol. 2019 Aug 15;26 (8) :1067-1080.e8. |Cell Chem Biol. 2025 Apr 17;32 (4) :556-569.e24.|Cell Death Dis. 2020 Sep 15;11 (9) :754.|Cell Rep Med. 2023 Oct 17;4 (10) :101200.|Cell Rep Methods. 2023 Oct 23;3 (10) :100599.|Cell Rep. 2017 Oct 31;21 (5) :1386-1398.|Cell Rep. 2020 Aug 4;32 (5) :107995.|Cell. 2023 Jun 8;186 (12) :2628-2643.e21.|Cell. 2025 Oct 30;188 (22) :6301-6316.e29.|Clin Cancer Res. 2015 Nov 1;21 (21) :4947-59.|Clin Cancer Res. 2025 Mar 3;31 (5) :907-920.|Department of Biochemistry. 2020 Oct.|Eur J Cancer. 2018 Oct:102:10-22.|Eur J Drug Metab Pharmacokinet. 2021 Sep;46 (5) :625-635.|Eur J Pharmacol. 2025 Sep 15:1003:177942.|Front Oncol. 2022 Apr 8;12:819003.|Fundam Clin Pharmacol. 2021 Oct;35 (5) :919-929.|Harvard Medical School LINCS LIBRARY|Int J Biol Macromol. 2024 Dec 27:139117.|Int J Biol Sci. 2019 Jan 1;15 (3) :522-532. |J Chromatogr B Analyt Technol Biomed Life Sci. 2020 Jun 15;1147:122142.|J Infect Dis. 2018 Nov 22;218 (suppl_5) :S365-S387.|J Pharm Biomed Anal. 2021 Apr 15:197:113933.|J Transl Med. 2022 May 13;20 (1) :217.|J Virol. 2023 Jun 29;97 (6) :e0037023.|Leuk Res. 2022 Sep:120:106920.|Mil Med Res. 2022 Dec 19;9 (1) :71.|Mol Cancer Ther. 2018 May;17 (5) :897-907.|Mol Cell. 2017 Oct 19;68 (2) :336-349.e6.|Mol Oncol. 2017 Aug;11 (8) :1035-1049.|Nat Commun. 2021 Sep 10;12 (1) :5386.|Nat Commun. 2022 Aug 10;13 (1) :4689.|Nat Commun. 2019 Jun 28;10 (1) :2860.|Nature Cancer. 2021 Apr;2 (4) :429-443.|Naunyn Schmiedebergs Arch Pharmacol. 2023 Jul;396 (7) :1435-1450.|NPJ Precis Oncol. 2021 Mar 19;5 (1) :20.|NPJ Precis Oncol. 2025 May 27;9 (1) :156.|Patent. US20220354911A1.|Pharmaceutics. 2025 Jul 25;17 (8) :967.|PLoS One. 2022 Dec 22;17 (12) :e0279522.|PLoS One. 2024 Aug 28;19 (8) :e0309289.|PLoS One. 2024 Nov 1;19 (11) :e0308647.|Research Square Print. November 7th, 2022|RSC Adv. 2020, 10 (38) :22668-22683.|Sci Adv. 2022 Dec 23;8 (51) :eadc8911.|Sci Rep. 2021 Mar 8;11 (1) :5374.|Sci Rep. 2022 Jul 20;12 (1) :12420.|Sci Transl Med. 2018 Jul 18;10 (450) :eaaq1093.|Texas Southern University. 2024 July 02.|Transl Oncol. 2024 Aug 16:49:102092.|University of Innsbruck. 2025.|University of Jena. 2025.|Biochem Pharmacol. 2025 Jan 9:116744.|bioRxiv. 2023 Sep 16:2023.09.15.554413.|Clin Cancer Res. 2015 Nov 1;21 (21) :4947-59.|JCI Insight. 2022 Feb 8;7 (3) :e154402.|Cell Chem Biol. 2018 Feb 15;25 (2) :135-142.e5.|Int J Mol Med. 2025 Nov;56 (5) :167.|Nat Commun. 2021 Aug 25;12 (1) :5112.

Chemical Information

Ribociclib

Ribociclib is a member of piperazines and a member of pyridines.

CAS Number1211441-98-3
PubChem CID44631912
IUPAC Name7-cyclopentyl-N,N-dimethyl-2-[(5-piperazin-1-yl-2-pyridinyl)amino]pyrrolo[2,3-d]pyrimidine-6-carboxamide
Molecular FormulaC23H30N8O
Molecular Weight434.5
XLogP2.2
Topological Polar Surface Area91.2
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count7
Rotatable Bond Count5
Heavy Atom Count32
Formal Charge0
Complexity635
SMILES
CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=NC=C(C=C4)N5CCNCC5
InChI
InChI=1S/C23H30N8O/c1-29(2)22(32)19-13-16-14-26-23(28-21(16)31(19)17-5-3-4-6-17)27-20-8-7-18(15-25-20)30-11-9-24-10-12-30/h7-8,13-15,17,24H,3-6,9-12H2,1-2H3,(H,25,26,27,28)
InChIKey
RHXHGRAEPCAFML-UHFFFAOYSA-N
Chemical Structure
2D Structure
2D structure of Ribociclib
CAS: 1211441-98-3
CID: 44631912
Formula: C23H30N8O
MW: 434.5
Interactive 3D Structure
Loading 3D structure...
View on PubChemRaw 3D data
Computed Properties
PropertyValue
Molecular Weight434.5
XLogP32.2
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count7
Rotatable Bond Count5
Exact Mass434.25425761
Monoisotopic Mass434.25425761
Topological Polar Surface Area91.2 Ų
Heavy Atom Count32
Formal Charge0
Complexity635
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently-Bonded Unit Count1
Compound Is CanonicalizedYes

Alternative Products

CatalogName
bs-83028C-01Ribociclib
CS-O-32732Ribociclib-d6
CS-O-32629Ribociclib-d8
9481-25Ribociclib (LEE011)
RM-R090201-01Ribociclib D6
M22128-01Ribociclib succinate
S5187-01Ribociclib hydrochloride

Popular Products